Gyre Therapeutics, Inc. Restructuring Charges
Gyre Therapeutics, Inc. (GYRE) reported Restructuring Charges of $1.01 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-30.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2023-03-30
- Gyre Therapeutics, Inc. restructuring charges for the quarter ending 2015-06-30 was $874.00K.
- Gyre Therapeutics, Inc. restructuring charges for the quarter ending 2015-03-31 was $1.16M.
- Gyre Therapeutics, Inc. restructuring charges for the quarter ending 2012-09-30 was $0.00.
- Gyre Therapeutics, Inc. restructuring charges for the quarter ending 2012-06-30 was $2.31M.
- Gyre Therapeutics, Inc. restructuring charges for fiscal 2022 was $1.01M, a 75.74% decline from fiscal 2021.
- Gyre Therapeutics, Inc. restructuring charges for fiscal 2021 was $4.17M.
- Gyre Therapeutics, Inc. restructuring charges for fiscal 2017 was $0.00.
| Period end | Restructuring Charges 3 month | Restructuring Charges 6 month | Restructuring Charges 9 month | Restructuring Charges 12 month |
|---|---|---|---|---|
| 2022-12-31 | $1.01M 10-K · filed 2023-03-30 | |||
| 2021-12-31 | $4.17M 10-K · filed 2023-03-30 | |||
| 2017-12-31 | $0.00 10-K · filed 2018-03-19 | |||
| 2015-06-30 | $874.00K 10-Q · filed 2015-07-31 | $2.03M 10-Q · filed 2015-07-31 | ||
| 2015-03-31 | $1.16M 10-Q · filed 2015-05-07 | |||
| 2012-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-06 | $2.31M derived: sum of 2 quarters · filed 2013-11-06 | $2.31M 10-Q · filed 2013-11-06 | |
| 2012-06-30 | $2.31M 10-Q · filed 2013-08-07 | $2.31M 10-Q · filed 2013-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |